Indaco Capital

Indaco Capital is a principal investment firm established in 2015 and located in Beijing, China. The firm focuses on early-stage investments in the healthcare sector, specifically targeting biomedicine, medical devices, and healthcare services. By concentrating on these industries, Indaco Capital aims to support innovation and development within the healthcare landscape.

Ye Wang

Partner

3 past transactions

Zenshine Pharma

Series A in 2020
Zenshine Pharma is a clinical-stage biopharmaceutical company with a focus on the development of small molecule drugs for cancer, viral infections, and autoimmune diseases.

Delova Biotech

Venture Round in 2020
Delova Biotech is focused on developing non-opioid analgesics aimed at pain treatment. The company leverages its extensive research and development experience, along with advanced preparation technology platforms, to enhance existing medications and create improved new analgesics in both China and the United States. Delova Biotech employs innovative technologies, including long-acting injection methods, transdermal formulations, nano-delivery systems, prodrug modifications, and techniques to improve the solubility of insoluble drugs. Through these efforts, the company strives to provide patients with higher quality medications that can significantly enhance their quality of life.

Acornmed

Series A in 2020
Beijing AcornMed Biotechnology Co., Ltd. researches, develops, and sales vitro diagnostic reagents and instruments in China. The company also offers testing services for lung cancer, colorectal cancer, urinary neoplasms, pan cancer, and blood tumor. Beijing AcornMed Biotechnology Co., Ltd. is based in Beijing, China.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.